Market Outlook

The U.S. CLIA-Waived Point-of-Care Testing Devices Market was valued at approximately USD 5.85 billion in 2025 and is projected to reach approximately USD 14.11 billion by 2035, expanding at a CAGR of 9.20% during 2026–2035. The historical market is estimated to have expanded from approximately USD 4.60 billion in 2021 to USD 5.41 billion in 2024, with demand progressively shifting from pandemic-led respiratory testing toward a more diversified mix of cardiometabolic screening, diabetes management, molecular infectious disease testing, urinalysis, sexual-health testing, coagulation, and decentralized primary-care diagnostics. Values in this report are expressed in USD billions.

Based on the modeled growth trajectory, the market is expected to reach approximately USD 6.39 billion in 2026, USD 9.08 billion by 2030, and USD 14.11 billion by 2035. Growth is expected to be materially faster in rapid molecular platforms, multi-analyte respiratory testing, decentralized sexual-health diagnostics, integrated cardiometabolic testing, and connected reader-based systems than in conventional single-analyte visual lateral-flow tests.

For the purpose of this report, the market covers professional-use diagnostic instruments, meters, readers, analyzers, cartridges, strips, cassettes, and test-specific consumables used at or near the patient under CLIA-waived testing conditions in the United States. The scope includes physician offices, urgent care centers, retail clinics and pharmacies, hospital point-of-care environments, community health centers, nursing and long-term-care facilities, public-health sites, mobile testing environments, and other authorized near-patient locations. It excludes conventional central-laboratory platforms, tests restricted to moderate- or high-complexity laboratories, and purely consumer-directed home self-testing where the test is neither performed nor interpreted by a professional testing site.

The commercial strength of the market comes from an unusual combination of regulatory simplicity and clinical immediacy. Waived testing allows healthcare organizations to move selected diagnostic decisions outside a traditional laboratory workflow without building the staffing and infrastructure associated with non-waived testing. This lowers deployment barriers for physician practices, pharmacies, urgent care operators, community clinics, and decentralized care networks while shortening the interval between specimen collection, result generation, diagnosis, prescribing, referral, and treatment.

The next decade will therefore be defined less by whether testing can technically be performed at the point of care and more by whether device manufacturers can deliver laboratory-relevant accuracy with consumer-grade simplicity, low operator burden, rapid turnaround time, digital connectivity, manageable quality-control requirements, and economically attractive per-test costs.

 

Introduction

The U.S. CLIA-Waived Point-of-Care Testing Devices Market represents one of the most strategically important segments within decentralized diagnostics. Under the Clinical Laboratory Improvement Amendments framework, waived tests are designed to be sufficiently simple and to carry a low risk of incorrect results when performed according to manufacturer instructions. This regulatory positioning allows many tests to be deployed in healthcare environments that would not economically or operationally support conventional laboratory testing.

The underlying addressable infrastructure is substantial. The U.S. CLIA program regulates roughly 320,000 laboratory entities, and Certificate of Waiver laboratories account for a significant majority of non-exempt testing sites. This broad installed testing base gives manufacturers a distribution opportunity extending well beyond hospitals. Physician offices, pharmacies, urgent care networks, federally supported community health centers, occupational health providers, nursing facilities, school clinics, public-health programs, and mobile testing operations can all represent viable channels when the test menu aligns with their clinical authority and workflow.

The market has also moved beyond the perception that waived testing is limited to basic glucose strips, pregnancy tests, urine dipsticks, and visually read infectious disease assays. Newer systems increasingly incorporate fluorescence readers, digital immunoassay interpretation, microfluidics, cartridge-based chemistry, rapid nucleic acid amplification, automated sample preparation, multiplex detection, connectivity, operator lockout controls, onboard quality functions, and cloud-based result management.

That progression is economically important. The value of a CLIA-waived device is increasingly measured by the clinical decision it allows during the patient encounter. A respiratory molecular test that differentiates influenza, SARS-CoV-2, and RSV before a patient leaves urgent care has different economics from a test requiring laboratory shipment and next-day follow-up. A point-of-care HbA1c result obtained during a primary-care visit can immediately influence therapy adjustment. A rapid sexual-health assay capable of supporting same-visit treatment can reduce loss to follow-up. A urine albumin-to-creatinine ratio test performed during routine diabetes management can help identify kidney-disease risk earlier.

U.S. healthcare delivery is particularly favorable to these use cases because outpatient encounters are fragmented across thousands of physician practices, urgent care sites, pharmacy locations, community health centers, outpatient departments, and retail-oriented care models. The economics of these sites depend heavily on throughput, labor utilization, patient retention, visit closure, prescribing efficiency, and avoidance of unnecessary referrals.

The market also benefits from the scale of the diseases being tested. Diabetes affects tens of millions of Americans, with an even larger prediabetes population. Respiratory viruses continue to generate millions of outpatient encounters. More than two million nationally reportable major sexually transmitted infections are identified annually, while HIV screening remains an important public-health priority. These clinical burdens create repeated testing opportunities rather than one-time capital-equipment demand.

Competition is consequently shifting toward installed-base strategy. Manufacturers that place a reader or analyzer in a physician office, urgent care chain, pharmacy network, or health system can generate recurring cartridge and consumable revenue. This makes menu breadth, instrument uptime, supply continuity, test economics, distributor access, interoperability, training burden, and reimbursement support as important as analytical performance.

 

Key Market Drivers: What Is Fueling the U.S. CLIA-Waived Point-of-Care Testing Devices Market?

A primary driver is the continued decentralization of diagnostic decision-making. Healthcare organizations are attempting to resolve more episodes of care during a single visit. Sending specimens to an external laboratory can delay treatment, create additional patient communication, increase administrative work, and raise the risk that patients do not return for follow-up. CLIA-waived testing directly addresses this friction by bringing selected laboratory decisions into the clinical encounter.

The scale of CLIA-certified infrastructure supports this transition. With hundreds of thousands of regulated laboratory entities across the U.S. and Certificate of Waiver sites representing a large proportion of the testing ecosystem, manufacturers do not need to rely exclusively on hospital laboratories. The market can instead be built through thousands of distributed clinical endpoints.

Expansion of pharmacy-based testing is another structural driver. The number of pharmacies holding CLIA waivers increased sharply during the pandemic and continued to increase thereafter. This matters strategically because pharmacy networks already possess accessible locations, established patient relationships, immunization infrastructure, pharmacists trained in clinical services, and high consumer traffic. Where state scope-of-practice rules and collaborative-care arrangements allow, pharmacies can become meaningful testing nodes for respiratory disease, infectious disease screening, cardiometabolic risk assessment, and other rapid diagnostic services.

Chronic metabolic disease creates a second major demand pillar. Approximately 38 million people in the U.S. have diabetes, while the prediabetes population is substantially larger. This generates sustained demand for glucose measurement, HbA1c testing, lipid assessment, urine albumin screening, renal-risk identification, and related near-patient diagnostics. Unlike seasonal infectious disease testing, these categories produce recurring utilization throughout the year and are linked to long-term primary-care management.

Respiratory disease testing remains commercially important even after the exceptional testing volumes of the COVID-19 emergency period. Seasonal influenza, RSV, SARS-CoV-2, group A streptococcal disease, and other respiratory infections continue to generate high outpatient volumes. The key change is that the market is moving from single-pathogen emergency testing toward routine differential diagnosis. Clinicians increasingly value platforms that can distinguish among pathogens associated with similar symptoms because the result can influence antiviral therapy, antibiotic stewardship, patient counseling, infection-control decisions, and escalation of care.

Sexual-health diagnostics provide another attractive growth opportunity. More than 2.4 million combined cases of chlamydia, gonorrhea, and syphilis were reported nationally in 2023, including approximately 1.65 million chlamydia cases. Rapid decentralized testing has significant clinical value because conventional laboratory workflows can create delays between testing and treatment. CLIA-waived molecular technologies capable of providing actionable results during the encounter may therefore capture increasing demand in urgent care, community health centers, reproductive-health settings, public-health clinics, and selected physician practices.

The HIV testing opportunity remains similarly important. Roughly 1.2 million Americans are estimated to be living with HIV, including a meaningful population unaware of their status. Waived rapid tests allow screening to occur in nontraditional settings and can support earlier linkage to confirmatory testing and treatment.

Healthcare access infrastructure is another demand catalyst. Federally supported health centers serve more than 32 million U.S. patients through a network exceeding 16,000 service-delivery sites. These environments are highly relevant for waived testing because they frequently care for populations facing barriers to transportation, specialty care, insurance coverage, and follow-up. A diagnostic result available during the same encounter can have disproportionately high operational and clinical value in these settings.

Hospital economics also influence adoption. Although CLIA-waived testing is strongly associated with outpatient care, hospitals remain important users through emergency departments, inpatient bedside testing, ambulatory clinics, procedural areas, and satellite locations. The U.S. hospital system includes more than 6,000 hospitals, approximately 907,000 staffed beds, and more than 35 million annual admissions. Point-of-care technologies that reduce laboratory turnaround time or accelerate clinical disposition can therefore generate measurable workflow value.

Finally, regulatory innovation is enlarging the addressable test menu. Recent FDA waiver decisions demonstrate that CLIA-waived testing is moving into multiplex respiratory diagnostics, molecular sexually transmitted infection testing, hematology, renal-risk assessment, urinalysis, and increasingly sophisticated automated platforms. Each new waiver can create a new decentralized workflow that was previously concentrated in conventional laboratories.

 

Innovation in Focus: How Manufacturers Are Raising the Bar

Innovation in this market is focused primarily on eliminating the historical trade-off between simplicity and diagnostic sophistication. Earlier generations of waived testing were dominated by low-cost strips and single-analyte visual assays. The emerging market increasingly includes systems capable of performing molecular amplification, quantitative immunoassays, multiplex pathogen detection, digital interpretation, automated quality assessment, and electronic result transmission while remaining usable by operators without specialized laboratory training.

Rapid molecular diagnostics are one of the most significant areas of innovation. Cartridge-based and self-contained molecular systems reduce sample-preparation steps and operator interaction while providing results within a clinically actionable visit window. Respiratory diagnostics have led this transition, but the same operating model is expanding into sexually transmitted infections and other infectious diseases. The commercial benefit is substantial because molecular testing can command higher per-test pricing than basic antigen assays when its improved sensitivity, multiplex capability, and clinical actionability justify the cost.

Multiplexing is becoming increasingly important. Urgent care clinicians frequently face patients with overlapping symptoms that could be caused by influenza, RSV, SARS-CoV-2, or bacterial infections. Running several independent assays can consume operator time, increase consumable cost, and complicate workflow. Integrated panels allow a single specimen and testing process to address several diagnostic possibilities, increasing the economic value of the platform.

Digital interpretation is another important innovation. Visual interpretation can introduce subjectivity, particularly around faint lines, timing windows, lighting conditions, and inexperienced operators. Reader-based systems standardize interpretation, record results electronically, reduce transcription errors, and create a platform for connectivity. This is particularly valuable for multi-site urgent care chains, hospital networks, and retail clinics that require centralized oversight of testing quality.

Connectivity is becoming a competitive differentiator rather than an optional feature. Health systems increasingly expect point-of-care results to flow into electronic medical records, laboratory information systems, middleware, population-health dashboards, and quality-reporting infrastructure. Manual result entry creates documentation risk and labor burden. Manufacturers able to provide device management, operator tracking, automatic result transfer, remote configuration, and fleet-level monitoring can become strategically embedded within customer workflows.

Sample-to-answer automation is also improving the commercial viability of waived molecular testing. The fewer pipetting, dilution, timing, mixing, or transfer steps an operator must perform, the easier a device is to scale across decentralized environments. Cartridge design, premeasured reagents, automatic timing, onboard controls, and error detection are therefore central to product development.

Cardiometabolic platforms are becoming more integrated as well. HbA1c, lipid testing, glucose testing, urine albumin-to-creatinine ratio measurement, and related assessments can increasingly be incorporated into structured chronic-disease visits. The opportunity for manufacturers is to move from selling an isolated assay to supporting a broader primary-care diagnostic pathway.

Another innovation theme is the convergence of diagnostic hardware and workflow software. Competitive platforms increasingly include connectivity, inventory monitoring, quality-control documentation, remote technical support, utilization analytics, and test-menu management. In a highly distributed CLIA-waived network, the ability to manage hundreds or thousands of devices centrally can materially influence purchasing decisions.

Manufacturers are also designing products around non-laboratory operators. Human-factors engineering, pictorial workflows, cartridge geometry, fail-safe controls, automated calibration, instrument prompts, barcode scanning, lockouts, and onboard QC are increasingly important because the commercial customer may be a nurse, medical assistant, pharmacist, clinic technician, or other healthcare worker rather than a trained medical technologist.

The next innovation cycle is likely to focus on higher-complexity clinical information delivered through lower-complexity user workflows. Companies that can achieve this without creating excessive per-test cost or reimbursement friction will have the strongest opportunity to expand the CLIA-waived testing universe.

 

Segmentation Insights

The U.S. CLIA-Waived Point-of-Care Testing Devices Market is segmented on the basis of test category, device and platform format, sample type, end user, and region.

 

By Test Category

Blood Glucose and Diabetes Testing

Blood glucose and diabetes-related testing represents one of the largest recurring revenue pools in the market, estimated at approximately USD 1.66 billion in 2025, or about 28% of total market value under the report scope. The category includes professional blood glucose meters and strips, HbA1c systems, and related waived diabetes-management assays.

Its commercial advantage is recurring utilization. Unlike episodic infectious disease tests, diabetes testing is integrated into longitudinal management across hospitals, physician practices, community health centers, pharmacies, and long-term-care environments. Expansion of HbA1c point-of-care testing and renal-risk screening should progressively shift value toward higher-priced quantitative systems.

Infectious Disease Testing

Infectious disease testing represented an estimated USD 1.58 billion in 2025, accounting for approximately 27% of market revenue. Respiratory antigen tests, rapid molecular respiratory assays, group A streptococcal tests, HIV testing, sexually transmitted infection assays, hepatitis testing, and selected other infectious disease diagnostics form this segment.

This is expected to be one of the fastest-growing categories, with growth potentially exceeding the total-market CAGR through 2035. The mix is moving toward molecular and multiplex testing because same-visit pathogen differentiation creates greater clinical value than undifferentiated symptomatic management.

Cardiometabolic and Lipid Testing

Cardiometabolic testing generated an estimated USD 0.92 billion in 2025. The segment includes cholesterol and lipid panels, selected cardiac-risk assessments, renal-risk markers, and other decentralized chemistry tests used in chronic disease management.

Demand is supported by the high prevalence of diabetes, obesity, hypertension, kidney disease, and cardiovascular risk. Primary-care practices and pharmacies are particularly attractive channels because point-of-care results can support immediate counseling and treatment decisions.

Pregnancy and Fertility Testing

Professional-use pregnancy and fertility testing represented approximately USD 0.51 billion in 2025. Urine pregnancy tests remain mature, low-cost, and highly penetrated. Growth is therefore likely to remain below molecular infectious disease and advanced cardiometabolic categories.

Demand nevertheless remains stable across physician offices, urgent care centers, emergency care, women’s health practices, public-health clinics, and community care environments because pregnancy status can influence prescribing, imaging, procedural, and treatment decisions.

Coagulation and Hematology Testing

Coagulation and waived hematology testing accounted for approximately USD 0.44 billion in 2025. The category includes selected prothrombin time/INR devices, hemoglobin and hematocrit testing, and newly expanding simplified hematology systems.

The emergence of waived CBC-type systems is strategically important because it moves an historically laboratory-oriented test category closer to the patient. Adoption will depend on clinical accuracy, cost per test, breadth of parameters, reimbursement, and whether decentralized testing produces sufficient time savings to offset cartridge costs.

Drugs of Abuse and Toxicology Testing

Drugs-of-abuse and related toxicology testing represented approximately USD 0.39 billion in 2025. Urine- and oral-fluid-based testing is used across physician offices, behavioral-health programs, occupational medicine, substance-use treatment, pain management, emergency settings, and other decentralized environments.

Growth is linked to opioid-use management, medication adherence, occupational screening, and the need for rapid preliminary results. Confirmation of certain results may still require reference laboratory testing, which limits the extent to which waived devices can replace conventional toxicology workflows.

Urinalysis, Renal and Other Waived Tests

Urinalysis, renal testing, fecal occult blood tests, selected chemistry assays, and other CLIA-waived categories collectively represented approximately USD 0.35 billion in 2025. This group is fragmented but commercially relevant because it supports broad primary-care and ambulatory workflows.

Renal screening represents an increasingly attractive subcategory as diabetes and hypertension management programs place greater emphasis on early kidney-disease identification.

 

By Device and Platform Format

Lateral Flow and Rapid Immunochromatographic Devices

Lateral-flow formats accounted for an estimated 28%–29% of 2025 market revenue. Their installed base remains large because they are inexpensive, portable, fast, and require limited equipment. Respiratory testing, pregnancy testing, infectious disease screening, and drugs-of-abuse testing remain major applications.

The principal competitive pressure on this segment comes from digital readers and molecular diagnostics, particularly where clinical decisions require higher sensitivity or multi-pathogen differentiation.

Meter-and-Strip Systems

Meter-and-strip systems represented approximately 26% of 2025 market value, led by professional glucose testing and related chronic-disease applications. Their economic model is highly recurring because meter placement drives ongoing strip utilization.

Connectivity, infection-control design, barcode capability, operator management, and integration with hospital or clinic data systems are becoming important differentiators in institutional purchasing.

Cartridge-Based Analyzer Systems

Cartridge-based immunoassay, chemistry, coagulation, and hematology platforms represented approximately 22% of 2025 revenue. These systems combine higher-value consumables with relatively compact instruments and are increasingly attractive to physician offices and multisite outpatient networks.

Their commercial success depends on menu breadth. A platform capable of supporting several clinically relevant tests generally produces stronger utilization economics than a single-purpose analyzer.

Rapid Molecular Platforms

Rapid molecular systems represented approximately 14% of 2025 market value but are expected to record the fastest platform growth, potentially at a low-double-digit CAGR through 2035. Respiratory and sexual-health testing are leading applications.

The segment benefits from premium pricing and diagnostic accuracy but faces cost-per-test, instrument-placement, reimbursement, and throughput constraints. Manufacturers that shorten run time and expand menu breadth can materially increase instrument utilization.

Dipsticks, Readers and Other Platforms

Urine dipsticks, digital urinalysis readers, optical readers, compact photometers, and other devices collectively accounted for approximately 9%–10% of market revenue. These platforms remain important in primary care because they offer low cost and high familiarity.

Automation of reading and result transfer should support gradual replacement of purely visual workflows, particularly in multisite networks seeking standardized documentation.

 

By Sample Type

Blood

Blood-based testing accounted for an estimated 47% of market revenue in 2025 and remains the largest sample category. Glucose, HbA1c, lipids, coagulation, hematology, hemoglobin, and selected infectious disease tests support this leadership.

Its position is expected to remain strong because chronic disease creates recurring year-round testing demand.

Nasal and Oropharyngeal Swabs

Respiratory swabs represented approximately 22% of market value in 2025. Demand is seasonal but high-volume, and the segment increasingly supports both antigen and molecular technologies.

Multiplex influenza, RSV, SARS-CoV-2, and sore-throat testing is expected to create higher average revenue per clinical episode.

Urine

Urine samples accounted for approximately 16% of 2025 revenue, supported by pregnancy testing, urinalysis, renal screening, toxicology, and selected sexually transmitted infection applications.

Automated interpretation and quantitative renal-risk measurements should support higher-value growth within what has historically been a low-cost testing category.

Saliva and Oral Fluid

Saliva and oral-fluid testing represented approximately 9% of market revenue. Drugs-of-abuse screening and selected infectious disease applications are important use cases.

The sample type is attractive because collection is non-invasive and can reduce some operational barriers associated with venipuncture or more invasive collection.

Other Samples

Other specimens collectively represented approximately 6% of market value and include stool, ocular samples, reproductive samples, and other specialized specimen types. This is a fragmented segment but provides opportunities for specialized developers targeting specific clinical workflows.

 

By End User

Physician Office Laboratories and Medical Practices

Physician offices represented an estimated 28% of 2025 market revenue, making them the largest individual professional end-user category. Primary care, pediatrics, internal medicine, women’s health, endocrinology, infectious disease, and other practices use waived testing to resolve routine diagnostic questions during the consultation.

Ease of operation, reimbursement visibility, compact instrument footprint, test-menu relevance, and the ability to eliminate follow-up calls are major purchasing considerations.

Urgent Care Centers, Retail Clinics and Pharmacies

Urgent care and retail-oriented testing environments accounted for approximately 25% of 2025 revenue and are expected to grow faster than the overall market. Respiratory infections, strep testing, pregnancy testing, urinalysis, glucose testing, and selected sexual-health diagnostics are especially relevant.

Pharmacy testing represents a strategic expansion channel. The rapid rise in pharmacy CLIA-waiver adoption demonstrates that testing infrastructure remains in place beyond the acute COVID period. The long-term opportunity depends on state practice rules, prescribing authority, reimbursement, payer contracting, and the ability to integrate testing into profitable clinical-service models.

Hospitals and Health-System Point-of-Care Locations

Hospitals and affiliated outpatient environments represented approximately 20% of market revenue. Glucose monitoring, coagulation, infectious disease testing, emergency diagnostics, and selected bedside tests are major applications.

Health systems place greater emphasis on connectivity, standardization, cybersecurity, fleet management, operator competency, enterprise contracting, quality documentation, and supply assurance than smaller independent practices.

Community Health Centers and Public-Health Settings

Community health centers and public-health organizations represented approximately 12% of market demand. These sites are important because they serve very large patient populations, including underserved and medically vulnerable groups for whom delayed diagnostic follow-up can be particularly problematic.

Testing for diabetes, HIV, sexually transmitted infections, respiratory pathogens, pregnancy, renal risk, and other primary-care conditions fits naturally into this environment.

Long-Term Care, Nursing, Occupational, Mobile and Other Sites

Long-term-care facilities, nursing settings, occupational health providers, mobile testing operations, correctional healthcare, school-based services, and other decentralized users collectively represented approximately 15% of 2025 revenue.

The segment favors simple, rugged devices with minimal maintenance, limited sample preparation, rapid results, and straightforward staff training. Long-term-care demand is particularly relevant for glucose and respiratory testing because of the vulnerability of older populations to metabolic instability and infectious disease outbreaks.

 

Regional Insights: Where the Market Is Growing Fastest

Regional performance in CLIA-waived point-of-care testing is determined less by hospital procedure intensity than by the distribution of outpatient healthcare sites, chronic disease prevalence, population growth, pharmacy-testing adoption, urgent care density, primary-care access, health-center networks, reimbursement conditions, and state-level rules governing pharmacist and non-physician testing services.

South

The South represented approximately USD 2.16 billion in 2025, equivalent to about 36.9% of the U.S. market, making it the largest regional opportunity. The region is projected to approach USD 5.22 billion by 2035, representing an approximately 9.2% CAGR.

The South includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, the District of Columbia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas.

Texas is one of the most strategically important state markets because of its population scale, extensive urgent care footprint, large physician-office base, strong retail pharmacy presence, expanding metropolitan healthcare networks, and high burden of diabetes and cardiometabolic disease. Houston, Dallas-Fort Worth, Austin, and San Antonio support dense networks of outpatient testing locations capable of adopting connected glucose, HbA1c, respiratory, urinalysis, and rapid molecular platforms.

Florida is similarly important but has a different demand structure. Its large older population strengthens demand for respiratory diagnostics, glucose monitoring, anticoagulation-related testing, renal screening, and rapid testing in long-term-care facilities. Florida also has a substantial urgent care, physician practice, pharmacy, and ambulatory healthcare infrastructure.

Georgia, North Carolina, Tennessee, and Virginia represent strong growth states because population expansion is combining with health-system investment and growing suburban outpatient capacity. Rapid respiratory testing, primary-care cardiometabolic screening, sexual-health diagnostics, and retail testing services should benefit.

Maryland, Delaware, Virginia, and the District of Columbia have comparatively dense healthcare infrastructures and sophisticated integrated systems, which support adoption of digitally connected analyzers and standardized point-of-care fleets.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia have significant diabetes, obesity, cardiovascular-risk, and rural-access burdens. These states therefore offer a different commercial opportunity: devices that allow diagnosis to be brought closer to patients rather than concentrating testing in large metropolitan laboratory networks. Community health centers, critical-access care environments, pharmacies, primary-care offices, and mobile programs can be especially important channels.

South Carolina similarly benefits from population growth, expanding retirement communities, and greater outpatient healthcare capacity.

The South should remain the largest regional revenue pool through 2035. The most successful commercial strategies will combine distributor reach with direct contracting across health systems, urgent care chains, pharmacy organizations, community health centers, and large physician groups rather than focusing exclusively on major hospitals.

West

The West accounted for approximately USD 1.34 billion in 2025, or about 22.9% of national revenue, and is projected to reach approximately USD 3.46 billion by 2035. With an estimated CAGR close to 10.0%, it is expected to be the fastest-growing U.S. region.

The West comprises Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.

California is the region’s largest market and one of the most important individual U.S. states for decentralized diagnostics. Its scale, large integrated health systems, academic medical centers, technology ecosystem, community health infrastructure, urgent care networks, and substantial managed-care penetration make it attractive for connected point-of-care platforms. California providers are particularly relevant for adoption of rapid molecular testing, digital result integration, sexual-health diagnostics, cardiometabolic screening, and population-health-oriented testing.

Washington and Oregon represent sophisticated provider markets with comparatively strong adoption of connected care and integrated delivery systems. Devices that can interface with enterprise IT architecture and support centralized device management are particularly relevant.

Arizona and Nevada are high-growth markets because population expansion and aging are increasing demand for outpatient and chronic-disease services. Diabetes testing, renal screening, respiratory diagnostics, and long-term-care testing are important categories.

Colorado and Utah combine population growth with advanced regional healthcare systems and expanding ambulatory networks. These states are attractive for integrated test platforms that support several assays from one compact analyzer.

New Mexico, Idaho, Montana, and Wyoming have more dispersed populations. In these states, the strategic value of CLIA-waived testing lies in overcoming geographic access barriers. Rural clinics, health centers, physician offices, pharmacies, and mobile care programs can use near-patient testing to avoid lengthy specimen transportation and delayed results.

Alaska presents an even more pronounced access case because of extreme geographic dispersion and logistical challenges in reaching conventional laboratory services. Compact systems with stable consumables, limited maintenance requirements, and strong technical-support infrastructure can have disproportionate value.

Hawaii represents a smaller absolute market but similarly benefits from distributed care needs across islands and from the importance of rapid testing in ambulatory, tourism-related, and community-care environments.

The West is expected to gain share because its provider organizations are relatively receptive to digitally integrated diagnostic systems, decentralized care models, and high-value rapid molecular technologies. California alone should remain one of the largest state-level opportunities nationally.

Northeast

The Northeast generated an estimated USD 1.28 billion in 2025, representing approximately 21.9% of the U.S. market, and is projected to reach approximately USD 3.02 billion by 2035, reflecting a CAGR of about 9.0%.

The Northeast includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania.

New York is the region’s largest market, supported by its population, physician density, hospital and health-system infrastructure, urgent care networks, community health centers, and large metropolitan patient base. New York City creates particularly strong demand for rapid respiratory, sexual-health, HIV, diabetes, and outpatient diagnostic testing.

Pennsylvania has a broad mix of major integrated delivery networks, academic centers, suburban outpatient systems, community hospitals, and rural healthcare markets. This creates opportunities across both high-end connected systems and simple decentralized devices.

New Jersey benefits from high population density, a large pharmaceutical and life-sciences ecosystem, strong commercial insurance penetration, and close integration with the New York and Philadelphia healthcare markets.

Massachusetts represents a smaller population market but has outsized strategic significance because of its academic medical centers, biotechnology ecosystem, sophisticated health systems, and willingness to evaluate new diagnostic technologies. Emerging molecular and multiplex platforms can gain early clinical validation and influential customer references in the state.

Connecticut and Rhode Island support dense metropolitan healthcare networks where connectivity and system standardization are important purchasing factors.

Maine, Vermont, and New Hampshire have smaller populations and more rural care needs. The commercial value proposition is therefore linked to access, specimen-transport avoidance, and rapid clinical decision-making in community hospitals, physician offices, health centers, long-term-care facilities, and other decentralized settings.

The Northeast is likely to remain a premium market where purchasing decisions are strongly influenced by analytical evidence, health-system standardization, informatics compatibility, and quality-management requirements. Growth will be somewhat constrained by population maturity but supported by adoption of higher-value molecular and digitally connected systems.

Midwest

The Midwest represented approximately USD 1.07 billion in 2025, or about 18.3% of national market revenue, and is forecast to approach USD 2.41 billion by 2035, reflecting an approximately 8.5% CAGR.

The Midwest includes Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

Illinois is the region’s largest individual opportunity, driven by the Chicago metropolitan healthcare market, large integrated delivery networks, community health services, physician groups, retail pharmacy infrastructure, and broad outpatient testing demand.

Ohio and Michigan represent large markets with substantial chronic disease burden, extensive hospital and physician networks, and major metropolitan areas. Diabetes testing, cardiometabolic assessment, respiratory diagnostics, urinalysis, and urgent care testing are important demand categories.

Minnesota has strategic relevance beyond its population because of its medtech ecosystem, sophisticated health systems, and longstanding concentration of diagnostic and medical-device expertise. It can be a valuable market for connected platforms and next-generation point-of-care technology.

Indiana, Wisconsin, and Missouri provide stable demand across community health systems, physician offices, retail pharmacies, occupational health, and urgent care. Growth is likely to be driven by platform replacement and expansion of higher-value test menus rather than by a dramatic increase in the number of care sites.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota are smaller markets but have strong use cases for decentralized testing because of rural geography and long specimen-transport distances. Health centers, critical-access hospitals, outpatient clinics, and pharmacies can obtain significant operational value from tests that eliminate laboratory send-outs for time-sensitive decisions.

The Midwest is expected to grow more slowly than the West and South but remain a durable market for both mature glucose and immunoassay systems and newer molecular platforms. Commercial success will depend strongly on distributor coverage, technical service, health-system contracting, predictable consumable pricing, and support for rural customers.

 

Key Market Players

The U.S. CLIA-Waived Point-of-Care Testing Devices Competitive Landscape is moderately concentrated at the platform level but highly fragmented across individual analytes. Large global diagnostics companies control major installed bases in glucose, respiratory testing, molecular diagnostics, immunoassays, and chemistry, while specialized developers continue to enter the market through targeted CLIA waiver approvals.

Important companies operating in or influencing the U.S. market include Abbott Laboratories; Roche Diagnostics; QuidelOrtho Corporation; Becton, Dickinson and Company; Siemens Healthineers; Cepheid; bioMérieux/BioFire Diagnostics; Nova Biomedical; OraSure Technologies; Sekisui Diagnostics; ACON Laboratories; DiaSorin Molecular; Visby Medical; Lumos Diagnostics; LEX Diagnostics; Nano-Ditech Corporation; Trinity Biotech; ARKRAY USA; PTS Diagnostics; HemoCue America; Universal Biosensors; EKF Diagnostics; Healgen Scientific; and Princeton BioMeditech Corporation.

Abbott has one of the broadest strategic positions because its portfolio touches professional glucose monitoring, HbA1c, lateral-flow infectious disease testing, cardiometabolic testing, and rapid molecular diagnostics. Instrument placements and high-volume consumables provide significant recurring-revenue potential.

Roche has strengthened its decentralized diagnostic position through cobas Liat molecular testing, glucose-related technologies, and investment in point-of-care platform capabilities. The ability to combine centralized laboratory relationships with decentralized testing is strategically important when health systems seek enterprise-level vendor consolidation.

QuidelOrtho remains highly relevant in rapid infectious disease testing through Sofia and other point-of-care diagnostic technologies. BD has a substantial presence through Veritor and broader institutional relationships.

Cepheid and bioMérieux/BioFire represent an important competitive direction: bringing molecular-level diagnostic information into near-patient environments. As CLIA-waived molecular menus expand, these companies compete not simply against other molecular systems but against conventional antigen testing and laboratory send-out workflows.

Nova Biomedical is increasingly important in professional glucose and compact decentralized testing. Its expansion into HbA1c and urine albumin-to-creatinine ratio testing strengthens its potential role in diabetes and kidney-disease management.

OraSure remains strategically relevant in rapid infectious disease and oral-fluid testing. Sekisui Diagnostics and ACON Laboratories participate across rapid infectious disease and urinalysis categories, while DiaSorin is expanding its point-of-care molecular relevance.

Emerging companies including Visby Medical, LEX Diagnostics, Lumos Diagnostics, Nano-Ditech, Healgen Scientific, and Princeton BioMeditech illustrate how the market remains accessible to focused innovators when they solve a specific clinical or workflow problem.

Competitive advantage through 2035 will increasingly be determined by five capabilities: the ability to obtain CLIA waiver for clinically valuable tests, build a meaningful assay menu around an installed platform, deliver reliable supply at scale, integrate results into provider information systems, and demonstrate economic value at the level of the patient encounter.

Manufacturers unable to provide connectivity, distribution, training, reimbursement support, and customer service will face increasing difficulty competing solely on analytical specifications.

 

Recent Developments

Recent FDA CLIA waiver activity demonstrates that the U.S. market is moving toward broader disease coverage and greater technological sophistication.

In March 2026, Lumos Diagnostics received a CLIA waiver decision for the FebriDx Bacterial/Non-Bacterial Assay, illustrating growing interest in point-of-care tests designed to help clinicians differentiate likely bacterial from non-bacterial acute respiratory illness. This category is strategically relevant to antimicrobial stewardship and same-visit treatment decisions.

In February 2026, LEX Diagnostics received a CLIA waiver decision for its VELO Respiratory Test, adding another molecular platform to the expanding decentralized respiratory diagnostics market.

In January 2026, Nano-Ditech received a waiver decision for its Nano-Check Influenza A+B Test, while Nova Biomedical received a waiver decision for its Nova Allegro UACR Assay. The UACR development is especially important because it demonstrates expansion of waived testing beyond acute infectious disease into chronic kidney-risk screening within diabetes management.

In late 2025, DiaSorin Molecular received a waiver decision for the LIAISON NES Flu A/B, RSV & COVID-19 assay, reinforcing the market trend toward multiplex respiratory testing.

Roche continued expanding the cobas Liat menu during 2025, including waived molecular tests for respiratory infections and sexually transmitted pathogens. Expanding menus improve instrument economics because the same installed analyzer can support more patient presentations throughout the year.

ACON Laboratories received waiver decisions across rapid strep and urinalysis technologies, supporting the continued relevance of lower-cost decentralized testing alongside premium molecular systems.

During 2025, the FDA also granted CLIA waiver decisions involving Visby Medical respiratory and sexual-health technologies, BioFire SPOTFIRE respiratory and sore-throat panels, Abbott BinaxNOW, BD Veritor, Sekisui influenza testing, Cepheid GeneXpert Xpress assays, and simplified hematology systems.

The broader strategic signal is more important than any individual approval. The CLIA-waived market is no longer defined by a narrow set of low-complexity legacy assays. The addressable menu is moving into multi-analyte molecular testing, quantitative chronic-disease management, kidney-risk testing, hematology, sexually transmitted infections, and clinically differentiated respiratory diagnostics.

Regulatory oversight is also evolving. Certificate of Waiver laboratories remain subject to less extensive requirements than non-waived laboratories, but federal policy has strengthened the ability to apply sanctions against noncompliant waived testing facilities. This increases the importance of manufacturer instructions, operator training, quality controls, traceability, device design, and remote fleet management.

From a commercial perspective, recent development activity favors companies capable of building platforms rather than isolated tests. A single waived assay can win a niche, but a growing menu improves analyzer utilization, customer retention, distributor economics, and switching costs.

 

Conclusion

The U.S. CLIA-Waived Point-of-Care Testing Devices Market is positioned to expand from approximately USD 5.85 billion in 2025 to USD 14.11 billion by 2035, representing a projected 9.20% CAGR during 2026–2035.

The central growth driver is the movement of diagnostically meaningful testing away from conventional laboratories and closer to the clinical decision. Physician offices, urgent care networks, pharmacies, community health centers, outpatient facilities, nursing environments, and other decentralized care sites increasingly require diagnostic information while the patient is still present.

The most attractive value pools are expected to emerge in rapid molecular diagnostics, multiplex respiratory testing, point-of-care sexual-health testing, quantitative diabetes management, kidney-risk assessment, connected testing platforms, and simplified hematology. Conventional glucose, pregnancy, urinalysis, and lateral-flow infectious disease tests will continue to generate significant recurring revenue, but their growth rates are likely to remain below newer platform categories.

The South will remain the largest regional market because of population scale, chronic disease burden, outpatient healthcare expansion, and large state markets including Texas and Florida. The West is expected to grow fastest, supported by California’s scale, technology adoption, integrated healthcare systems, and expanding populations in states such as Arizona, Nevada, Colorado, and Utah. The Northeast will remain a premium, evidence-driven market, while the Midwest will provide stable demand and meaningful opportunities for decentralized testing in rural areas.

At the competitive level, the most important question for clients is not simply which company has the most CLIA-waived assays. The strategic issue is which companies can convert regulatory waiver into an economically durable installed platform.

Winning vendors will need to demonstrate that their devices reduce diagnostic turnaround time, eliminate unnecessary laboratory send-outs, support same-visit treatment, integrate with clinical information systems, simplify operator workflow, maintain supply reliability, and produce a cost per actionable clinical decision that is attractive to U.S. providers.

The market’s next phase will therefore be driven by the convergence of regulatory simplicity, molecular-level diagnostic capability, decentralized care economics, and digital connectivity. Companies able to deliver those four attributes in a scalable platform are likely to capture a disproportionate share of U.S. CLIA-waived point-of-care testing growth through 2035.

 

TABLE OF CONTENT

1. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. CLIA-Waived Point-of-Care Testing Device Manufacturers
1.6.2. Assay, Reagent, Cartridge and Test-Strip Suppliers
1.6.3. Component, Biosensor and Contract Manufacturing Suppliers
1.6.4. Physician Office Laboratories and Medical Practices
1.6.5. Urgent Care Centers, Retail Clinics and Pharmacies
1.6.6. Hospitals and Integrated Health Systems
1.6.7. Community Health Centers and Public Health Organizations
1.6.8. Long-Term Care and Nursing Facilities
1.6.9. Distributors and Group Purchasing Organizations
1.6.10. CMS, FDA, CDC, Payers and Other Regulatory Stakeholders

What this section provides: This section defines the market boundary, study scope, methodology, assumptions, testing-site ecosystem, and stakeholder structure used to measure and validate the U.S. CLIA-waived point-of-care testing devices market.

2. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, CAGR and Revenue Opportunity Assessment
2.8. Fastest-Growing Test Categories
2.9. High-Growth Point-of-Care Platform Opportunities
2.10. Priority End-User and Testing-Site Opportunities
2.11. Regional and State-Level Opportunity Snapshot
2.12. Key Strategic Findings for Market Participants

What this section provides: This section gives decision-makers a concise view of market size, CAGR, historical performance, forecast direction, test-volume drivers, competitive intensity, regional opportunities, and the highest-value commercial opportunities through 2035.

3. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of Decentralized and Near-Patient Diagnostic Testing
3.1.2. Large Installed Base of CLIA Certificate of Waiver Testing Sites
3.1.3. Increasing Demand for Same-Visit Diagnosis and Treatment
3.1.4. High U.S. Diabetes and Cardiometabolic Disease Burden
3.1.5. Sustained Respiratory Infectious Disease Testing Demand
3.1.6. Expansion of Rapid Molecular and Multiplex Diagnostics
3.1.7. Growing Pharmacy-Based Point-of-Care Testing Infrastructure
3.1.8. Expansion of Urgent Care and Retail Healthcare Delivery
3.1.9. Increasing Need for Rapid STI and Sexual Health Diagnostics
3.1.10. Growing Community Health Center and Rural Testing Requirements
3.2. Restraints and Their Impact Analysis
3.2.1. Reimbursement Variability Across CLIA-Waived Tests
3.2.2. Price Pressure in Mature Lateral-Flow and Strip-Based Tests
3.2.3. Higher Per-Test Cost of Rapid Molecular Diagnostics
3.2.4. Operator Training and Quality-Control Requirements
3.2.5. Laboratory Confirmation Requirements for Selected Tests
3.2.6. Test Accuracy and False Positive/Negative Risk
3.2.7. State-Level Differences in Pharmacy Testing Authority
3.2.8. Supply-Chain Dependence for Reagents and Disposable Consumables
3.3. Opportunities and Their Impact Analysis
3.3.1. Rapid Molecular Respiratory Testing
3.3.2. Multiplex Influenza, RSV and SARS-CoV-2 Testing
3.3.3. CLIA-Waived Molecular STI Testing
3.3.4. Point-of-Care HbA1c and Diabetes Management
3.3.5. Urine Albumin-to-Creatinine Ratio and Kidney Risk Screening
3.3.6. CLIA-Waived Hematology and CBC Testing
3.3.7. Pharmacy Test-to-Treat Models
3.3.8. Rural and Mobile Diagnostic Testing
3.3.9. Connected Point-of-Care Testing Networks
3.3.10. Multi-Assay Analyzer Platform Expansion
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Laboratory-Grade Performance in Waived Workflows
3.4.2. Managing Multi-Site Operator Compliance
3.4.3. Connectivity and Electronic Health Record Integration
3.4.4. Consumable Inventory and Shelf-Life Management
3.4.5. Seasonal Testing Volume Volatility
3.4.6. Customer Conversion from Central Laboratory Testing
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Point-of-Care Device and Consumable Procurement Behavior Analysis
3.8. Cost per Actionable Diagnostic Result Analysis
3.9. Laboratory Send-Out Avoidance Economics
3.10. Test-to-Treatment Turnaround Time Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, operational, and technological forces shaping U.S. CLIA-waived testing demand and helps clients evaluate growth catalysts, barriers to adoption, workflow economics, and execution risks.

4. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Raw Material, Reagent and Disposable Consumable Analysis
4.6. Distribution and Point-of-Care Channel Ecosystem
4.7. Impact of Digitalization and Connected Diagnostics
4.8. Point-of-Care Connectivity, Middleware and EHR Integration Landscape
4.9. Application & Innovation Landscape
4.10. FDA In Vitro Diagnostic Regulatory Framework Analysis
4.11. CLIA Waiver Regulatory Pathway Analysis
4.12. CMS CLIA Certificate of Waiver Landscape
4.13. CMS Reimbursement and Coverage Landscape
4.14. CPT Coding and Test Reimbursement Environment
4.15. State Scope-of-Practice Considerations for Pharmacy Testing
4.16. Import/Export Restrictions & Tariff Impact
4.17. Government Initiatives and Public Health Programs
4.18. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.19. Hospital and Health-System Value Analysis Committee Decision Framework
4.20. Physician Office and Urgent Care Purchasing Decision Framework

What this section provides: This section gives clients a complete view of the external market environment, including CLIA regulation, FDA oversight, reimbursement, pricing, connectivity, supply chains, procurement behavior, public-health policy, and competitive barriers influencing commercial adoption.

5. U.S. CLIA-Waived Point-of-Care Testing Devices Market – By Test Category

5.1. Overview
5.1.1. Segment Share Analysis, By Test Category, 2025 & 2035 (%)
5.1.2. Blood Glucose and Diabetes Testing
5.1.2.1. Professional Blood Glucose Testing
5.1.2.2. HbA1c Testing
5.1.2.3. Other Diabetes-Related CLIA-Waived Tests
5.1.3. Infectious Disease Testing
5.1.3.1. Influenza Testing
5.1.3.2. SARS-CoV-2 Testing
5.1.3.3. RSV Testing
5.1.3.4. Multiplex Respiratory Testing
5.1.3.5. Group A Streptococcus Testing
5.1.3.6. HIV Testing
5.1.3.7. Sexually Transmitted Infection Testing
5.1.3.8. Hepatitis Testing
5.1.3.9. Other Infectious Disease Testing
5.1.4. Cardiometabolic and Lipid Testing
5.1.4.1. Total Cholesterol Testing
5.1.4.2. Lipid Panel Testing
5.1.4.3. Cardiovascular Risk Testing
5.1.4.4. Other Cardiometabolic Testing
5.1.5. Pregnancy and Fertility Testing
5.1.5.1. Pregnancy Testing
5.1.5.2. Fertility and Reproductive Health Testing
5.1.6. Coagulation and Hematology Testing
5.1.6.1. PT/INR Testing
5.1.6.2. Hemoglobin and Hematocrit Testing
5.1.6.3. CLIA-Waived CBC and Hematology Testing
5.1.7. Drugs of Abuse and Toxicology Testing
5.1.7.1. Urine-Based Drug Testing
5.1.7.2. Oral Fluid Drug Testing
5.1.7.3. Other Toxicology Testing
5.1.8. Urinalysis, Renal and Other CLIA-Waived Testing
5.1.8.1. Routine Urinalysis
5.1.8.2. Urine Albumin-to-Creatinine Ratio Testing
5.1.8.3. Fecal Occult Blood Testing
5.1.8.4. Other CLIA-Waived Tests

What this section provides: This section identifies the clinical test categories generating the greatest revenue and test-volume opportunities and evaluates which waived assays are positioned for the strongest expansion through 2035.

6. U.S. CLIA-Waived Point-of-Care Testing Devices Market – By Device & Platform Format

6.1. Overview
6.1.1. Segment Share Analysis, By Device & Platform Format, 2025 & 2035 (%)
6.1.2. Lateral Flow and Rapid Immunochromatographic Devices
6.1.2.1. Visually Read Lateral Flow Tests
6.1.2.2. Digital Reader-Assisted Lateral Flow Tests
6.1.2.3. Fluorescence Immunoassay Platforms
6.1.3. Meter-and-Strip Systems
6.1.3.1. Professional Blood Glucose Meters
6.1.3.2. Connected Meter Systems
6.1.3.3. Test Strips and Related Consumables
6.1.4. Cartridge-Based Analyzer Systems
6.1.4.1. Immunoassay Analyzers
6.1.4.2. Chemistry Analyzers
6.1.4.3. Coagulation Analyzers
6.1.4.4. Hematology Analyzers
6.1.5. Rapid Molecular Platforms
6.1.5.1. PCR-Based Platforms
6.1.5.2. Isothermal Amplification Platforms
6.1.5.3. Multiplex Molecular Platforms
6.1.5.4. Sample-to-Answer Molecular Systems
6.1.6. Dipsticks, Digital Readers and Other Platforms
6.1.6.1. Urinalysis Dipsticks
6.1.6.2. Digital Urinalysis Readers
6.1.6.3. Compact Photometric Systems
6.1.6.4. Other CLIA-Waived Device Formats

What this section provides: This section evaluates the relative attractiveness of major diagnostic device formats, including established lateral-flow and meter systems as well as rapidly expanding cartridge-based, digitally interpreted, and molecular platforms.

7. U.S. CLIA-Waived Point-of-Care Testing Devices Market – By Sample Type

7.1. Overview
7.1.1. Segment Share Analysis, By Sample Type, 2025 & 2035 (%)
7.1.2. Blood
7.1.2.1. Capillary Whole Blood
7.1.2.2. Venous Whole Blood
7.1.2.3. Plasma and Serum-Compatible Waived Testing
7.1.3. Nasal and Oropharyngeal Swabs
7.1.3.1. Anterior Nasal Swabs
7.1.3.2. Nasopharyngeal Swabs
7.1.3.3. Throat/Oropharyngeal Swabs
7.1.4. Urine
7.1.4.1. Routine Urinalysis Samples
7.1.4.2. Pregnancy Testing Samples
7.1.4.3. Toxicology Samples
7.1.4.4. Renal Screening Samples
7.1.4.5. Sexual Health Testing Samples
7.1.5. Saliva and Oral Fluid
7.1.5.1. Infectious Disease Testing
7.1.5.2. Drugs-of-Abuse Testing
7.1.5.3. Other Oral Fluid Applications
7.1.6. Other Sample Types
7.1.6.1. Stool Samples
7.1.6.2. Reproductive and Genital Samples
7.1.6.3. Ocular and Other Specialized Samples

What this section provides: This section analyzes demand according to specimen type and helps clients understand how sample collection complexity, patient convenience, workflow requirements, and test-menu expansion influence device adoption.

8. U.S. CLIA-Waived Point-of-Care Testing Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Physician Office Laboratories and Medical Practices
8.1.2.1. Primary Care Practices
8.1.2.2. Pediatric Practices
8.1.2.3. Women’s Health and OB/GYN Practices
8.1.2.4. Endocrinology and Diabetes Practices
8.1.2.5. Specialty Physician Practices
8.1.3. Urgent Care Centers, Retail Clinics and Pharmacies
8.1.3.1. Independent Urgent Care Centers
8.1.3.2. Multi-Site Urgent Care Networks
8.1.3.3. Retail Clinics
8.1.3.4. Community Pharmacies
8.1.3.5. National and Regional Pharmacy Chains
8.1.4. Hospitals and Health-System Point-of-Care Locations
8.1.4.1. Emergency Departments
8.1.4.2. Inpatient Bedside Testing
8.1.4.3. Hospital Outpatient Departments
8.1.4.4. Satellite and Ambulatory Clinics
8.1.5. Community Health Centers and Public Health Settings
8.1.5.1. Federally Qualified Health Centers
8.1.5.2. Community Health Centers
8.1.5.3. Public Health Clinics
8.1.5.4. Sexual Health and STI Clinics
8.1.5.5. Mobile and Outreach Testing Programs
8.1.6. Long-Term Care, Nursing, Occupational and Other Settings
8.1.6.1. Skilled Nursing Facilities
8.1.6.2. Assisted Living Facilities
8.1.6.3. Occupational Health Centers
8.1.6.4. Behavioral Health and Substance Use Treatment Centers
8.1.6.5. Correctional Healthcare
8.1.6.6. School and University Health Centers
8.1.6.7. Other Decentralized Testing Locations

What this section provides: This section explains which healthcare settings and testing-site categories generate the largest device and consumable demand and where manufacturers should prioritize commercial deployment and installed-base expansion.

9. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Access, Reimbursement & Commercialization Analysis

9.1. Overview
9.2. CLIA Certificate of Waiver Testing-Site Economics
9.3. CPT Coding and Reimbursement Analysis
9.4. Medicare Payment Environment for Waived Testing
9.5. Commercial Payer Reimbursement Dynamics
9.6. Physician Office Laboratory Economics
9.7. Urgent Care Testing Economics
9.8. Pharmacy Point-of-Care Testing Business Models
9.9. Community Health Center Testing Economics
9.10. Hospital Point-of-Care Testing Economics
9.11. Instrument Placement and Reagent Rental Models
9.12. Direct Manufacturer Contracting
9.13. National and Regional Distributor Networks
9.14. Group Purchasing Organization Influence
9.15. Integrated Delivery Network Standardization
9.16. Retail Pharmacy Chain Contracting
9.17. Multi-Site Urgent Care Contracting
9.18. Instrument Installed-Base and Recurring Consumable Strategy
9.19. Customer Switching Costs and Platform Lock-In Analysis
9.20. Test Menu Expansion and Analyzer Utilization Economics

What this section provides: This section explains how CLIA-waived devices reach U.S. customers, how testing economics interact with reimbursement, and how instrument placement, recurring consumables, distributors, IDNs, pharmacies, and urgent care networks influence commercial success.

10. U.S. CLIA-Waived Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional CLIA Certificate of Waiver Testing-Site Analysis
10.1.4. Regional Disease Burden and Testing Demand Analysis
10.1.5. Regional Physician Office, Urgent Care and Pharmacy Infrastructure
10.1.6. Regional Reimbursement and Procurement Dynamics
10.1.7. Regional Rapid Molecular Testing Adoption Analysis
10.1.8. Regional Market Attractiveness and Opportunity Index
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, Testing-Site and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region CLIA-Waiver Density, Retail Testing and Decentralized Care Adoption Analysis
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, Testing-Site and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region CLIA-Waiver Density, Retail Testing and Decentralized Care Adoption Analysis
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, Testing-Site and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region CLIA-Waiver Density, Retail Testing and Decentralized Care Adoption Analysis
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.24. Delaware
10.4.24.1. Overview
10.4.24.2. Delaware Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.4.24.3. Delaware Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.4.24.4. Delaware Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.4.24.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, Testing-Site and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region CLIA-Waiver Density, Retail Testing and Decentralized Care Adoption Analysis
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Test Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Device & Platform Format, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Sample Type, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and all-50-state market analysis, helping clients identify high-value testing geographies, CLIA-waiver concentration, disease-driven demand pockets, pharmacy and urgent care opportunities, rural access requirements, platform-adoption hotspots, and state-level commercialization priorities.

11. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking
11.3.1. Test Menu Breadth
11.3.2. CLIA-Waived Assay Portfolio
11.3.3. Instrument Installed Base
11.3.4. Rapid Molecular Capability
11.3.5. Connectivity and Digital Integration
11.3.6. Distribution Reach
11.3.7. Pharmacy and Urgent Care Penetration
11.3.8. Pricing and Reimbursement Support
11.3.9. Product Pipeline and Regulatory Momentum
11.4. Company Profiles
11.4.1. Abbott Laboratories
11.4.2. Roche Diagnostics
11.4.3. QuidelOrtho Corporation
11.4.4. Becton, Dickinson and Company
11.4.5. Siemens Healthineers
11.4.6. Cepheid
11.4.7. bioMérieux / BioFire Diagnostics
11.4.8. Nova Biomedical
11.4.9. OraSure Technologies
11.4.10. Sekisui Diagnostics
11.4.11. ACON Laboratories
11.4.12. DiaSorin Molecular
11.4.13. Visby Medical
11.4.14. Lumos Diagnostics
11.4.15. LEX Diagnostics
11.4.16. Nano-Ditech Corporation
11.4.17. Trinity Biotech
11.4.18. ARKRAY USA
11.4.19. PTS Diagnostics
11.4.20. HemoCue America
11.4.21. Universal Biosensors
11.4.22. EKF Diagnostics
11.4.23. Healgen Scientific
11.4.24. Princeton BioMeditech Corporation

Note: Each company profile will include company overview, U.S. CLIA-waived product portfolio, key analyzers and assays, installed-base strategy, commercial positioning, U.S. distribution network, FDA/CLIA waiver activity, innovation pipeline, strategic partnerships, competitive strengths, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, platform positioning, CLIA-waived test-menu breadth, regulatory momentum, installed-base strategy, innovation direction, and strategic intelligence on leading and emerging U.S. market participants.

12. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Rapid Sample-to-Answer Molecular Diagnostics
12.2.2. Multiplex Respiratory Testing
12.2.3. Digital Immunoassay Interpretation
12.2.4. CLIA-Waived Hematology Platforms
12.2.5. Microfluidic Point-of-Care Diagnostics
12.2.6. Biosensor-Based Quantitative Testing
12.2.7. AI-Assisted Result Interpretation
12.2.8. Connected Point-of-Care Device Networks
12.2.9. Cloud-Based Quality and Device Management
12.2.10. Multi-Assay and Multi-Disease Testing Platforms
12.3. Future CLIA-Waived Test Menu Expansion
12.4. Pharmacy Test-to-Treat Outlook
12.5. Urgent Care Diagnostic Platform Outlook
12.6. Physician Office Laboratory Transformation
12.7. Rural and Mobile Testing Outlook
12.8. Emerging Business Trends
12.9. Business Opportunities for Startups and Existing Players
12.10. M&A and Strategic Partnership Outlook
12.11. Investment Prioritization Matrix
12.12. White-Space Opportunity Analysis
12.13. Market Opportunity Heat Map, 2026–2035

What this section provides: This section prepares clients for future diagnostic platform shifts, expansion of the CLIA-waived test menu, changes in decentralized care delivery, emerging business models, market-entry opportunities, investment priorities, and adoption scenarios through 2035.

13. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Point-of-Care Diagnostic Device Manufacturers
13.2. Recommendations for Assay and Consumable Manufacturers
13.3. Recommendations for Hospitals and Integrated Health Systems
13.4. Recommendations for Physician Office Laboratories
13.5. Recommendations for Urgent Care and Retail Clinic Operators
13.6. Recommendations for Pharmacy Chains
13.7. Recommendations for Community Health Centers and Public Health Organizations
13.8. Recommendations for Investors and Private Equity Firms
13.9. Recommendations for Distributors and Channel Partners
13.10. Recommendations for New Entrants and Startups
13.11. CLIA Waiver Regulatory Strategy Considerations
13.12. U.S. Market Entry Strategy
13.13. Go-to-Market Strategy Considerations
13.14. Test Menu and Portfolio Expansion Guidance
13.15. Instrument Placement Strategy
13.16. Pricing and Reimbursement Strategy
13.17. Distribution and Channel Expansion Strategy
13.18. Pharmacy and Urgent Care Commercialization Strategy
13.19. Geographic Expansion and State Prioritization Strategy
13.20. Product Positioning and Competitive Differentiation Guidance

What this section provides: This section converts market intelligence into actionable recommendations for product development, CLIA waiver strategy, reimbursement planning, market entry, platform placement, channel expansion, state prioritization, investment decisions, and long-term competitive differentiation.

14. U.S. CLIA-Waived Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing Limitation
14.4. Forecasting Limitation
14.5. Regulatory and Reimbursement Data Limitation
14.6. Legal Disclaimer
14.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope, market-sizing methodology boundaries, regulatory and reimbursement considerations, data-use terms, legal limitations, third-party information treatment, and forecasting assumptions.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. CLIA-Waived Point-of-Care Testing Devices Market: High-Growth Opportunity Areas, 2026–2035
TABLE 14: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Point-of-Care Device Procurement Behavior Matrix
TABLE 21: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Cost per Actionable Diagnostic Result Analysis
TABLE 22: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Laboratory Send-Out Avoidance Economics
TABLE 23: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Test-to-Treatment Turnaround Time Analysis
TABLE 24: U.S. CLIA-Waived Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 25: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 28: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 29: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Reagent, Cartridge and Consumables Analysis
TABLE 30: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Distribution and Channel Ecosystem
TABLE 31: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Digitalization, Connectivity and EHR Integration
TABLE 32: U.S. CLIA-Waived Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 33: U.S. CLIA-Waived Point-of-Care Testing Devices Market: CLIA Waiver Regulatory Pathway Analysis
TABLE 34: U.S. CLIA-Waived Point-of-Care Testing Devices Market: CMS Certificate of Waiver Landscape
TABLE 35: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Reimbursement and CPT Coding Landscape
TABLE 36: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Pharmacy Scope-of-Practice Landscape
TABLE 37: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 38: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Government Initiatives and Public Health Programs
TABLE 39: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Geopolitical and Supply-Chain Risk Analysis
TABLE 40: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Buyer and Value Analysis Decision Framework
TABLE 41: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Test Category Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Test Category
TABLE 43: U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Test Category, 2021–2035 (US$ Billion)
TABLE 44: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Segment Share Analysis, by Test Category, 2025 & 2035 (%)
TABLE 45: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Blood Glucose and Diabetes Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Cardiometabolic and Lipid Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Pregnancy and Fertility Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Coagulation and Hematology Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Drugs of Abuse and Toxicology Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Urinalysis, Renal and Other Waived Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Device & Platform Format Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by Device & Platform Format
TABLE 54: U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Device & Platform Format, 2021–2035 (US$ Billion)
TABLE 55: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Segment Share Analysis, by Device & Platform Format, 2025 & 2035 (%)
TABLE 56: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Lateral Flow and Rapid Immunochromatographic Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Meter-and-Strip Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Cartridge-Based Analyzer Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Rapid Molecular Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Dipsticks, Digital Readers and Other Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Sample Type Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Sample Type
TABLE 63: U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 64: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Segment Share Analysis, by Sample Type, 2025 & 2035 (%)
TABLE 65: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Blood Sample Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Nasal and Oropharyngeal Swab Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Urine Sample Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Saliva and Oral Fluid Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Other Sample Types Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. CLIA-Waived Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by End User
TABLE 72: U.S. CLIA-Waived Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 73: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 74: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Physician Office Laboratories and Medical Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Urgent Care Centers, Retail Clinics and Pharmacies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Hospitals and Health-System Point-of-Care Locations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Community Health Centers and Public Health Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Long-Term Care, Nursing, Occupational and Other Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. CLIA-Waived Point-of-Care Testing Devices Market: CLIA Certificate of Waiver Testing-Site Economics
TABLE 80: U.S. CLIA-Waived Point-of-Care Testing Devices Market: CPT Coding and Reimbursement Analysis
TABLE 81: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Medicare Payment Environment
TABLE 82: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Commercial Payer Reimbursement Dynamics
TABLE 83: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Physician Office Laboratory Economics
TABLE 84: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Urgent Care Testing Economics
TABLE 85: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Pharmacy Point-of-Care Testing Business Models
TABLE 86: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Community Health Center Testing Economics
TABLE 87: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Hospital Point-of-Care Testing Economics
TABLE 88: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Instrument Placement and Reagent Rental Models
TABLE 89: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Procurement, Distribution, IDN and GPO Channel Matrix
TABLE 90: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Installed-Base, Menu Expansion and Recurring Consumables Economics
TABLE 91: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 92: Segment Dashboard; Definition and Scope, by Geography
TABLE 93: U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 94: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 95: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional CLIA-Waiver Testing-Site Density Analysis
TABLE 96: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Disease Burden and Testing Demand Analysis
TABLE 97: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Physician Office, Urgent Care and Pharmacy Infrastructure
TABLE 98: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Reimbursement and Procurement Dynamics
TABLE 99: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Market Attractiveness and Opportunity Index
TABLE 100: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 101: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Manufacturers and Testing-Site Ecosystem
TABLE 102: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Test Category, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Device & Platform Format, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 106: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: California CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Washington CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Arizona CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Colorado CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Oregon CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Utah CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Nevada CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 114: New Mexico CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Idaho CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Montana CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Wyoming CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Alaska CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Hawaii CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 121: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Manufacturers and Testing-Site Ecosystem
TABLE 122: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 123: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Test Category, 2021–2035 (US$ Billion)
TABLE 124: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Device & Platform Format, 2021–2035 (US$ Billion)
TABLE 125: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 126: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: New York CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Massachusetts CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 129: New Jersey CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Pennsylvania CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Connecticut CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Maine CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Vermont CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 134: New Hampshire CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Rhode Island CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 137: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Manufacturers and Testing-Site Ecosystem
TABLE 138: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 139: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Test Category, 2021–2035 (US$ Billion)
TABLE 140: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Device & Platform Format, 2021–2035 (US$ Billion)
TABLE 141: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 142: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: Texas CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Florida CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Georgia CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 146: North Carolina CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Tennessee CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 148: South Carolina CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Alabama CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Mississippi CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Louisiana CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Arkansas CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Kentucky CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Oklahoma CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Virginia CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Maryland CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 157: West Virginia CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Delaware CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 160: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Manufacturers and Testing-Site Ecosystem
TABLE 161: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 162: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Test Category, 2021–2035 (US$ Billion)
TABLE 163: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Device & Platform Format, 2021–2035 (US$ Billion)
TABLE 164: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by Sample Type, 2021–2035 (US$ Billion)
TABLE 165: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: Illinois CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Ohio CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Michigan CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Minnesota CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Indiana CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Wisconsin CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 172: Missouri CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 173: Iowa CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 174: Kansas CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 175: Nebraska CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 176: North Dakota CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 177: South Dakota CLIA-Waived Point-of-Care Testing Devices Market Size, Share and Forecast, 2021–2035 (US$ Billion)
TABLE 178: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 179: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 180: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 181: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Test Menu and Product Portfolio Benchmarking
TABLE 182: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Installed Base, Connectivity and Channel Benchmarking
TABLE 183: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 184: Abbott Laboratories: Company Profile
TABLE 185: Roche Diagnostics: Company Profile
TABLE 186: QuidelOrtho Corporation: Company Profile
TABLE 187: Becton, Dickinson and Company: Company Profile
TABLE 188: Siemens Healthineers: Company Profile
TABLE 189: Cepheid: Company Profile
TABLE 190: bioMérieux / BioFire Diagnostics: Company Profile
TABLE 191: Nova Biomedical: Company Profile
TABLE 192: OraSure Technologies: Company Profile
TABLE 193: Sekisui Diagnostics: Company Profile
TABLE 194: ACON Laboratories: Company Profile
TABLE 195: DiaSorin Molecular: Company Profile
TABLE 196: Visby Medical: Company Profile
TABLE 197: Lumos Diagnostics: Company Profile
TABLE 198: LEX Diagnostics: Company Profile
TABLE 199: Nano-Ditech Corporation: Company Profile
TABLE 200: Trinity Biotech: Company Profile
TABLE 201: ARKRAY USA: Company Profile
TABLE 202: PTS Diagnostics: Company Profile
TABLE 203: HemoCue America: Company Profile
TABLE 204: Universal Biosensors: Company Profile
TABLE 205: EKF Diagnostics: Company Profile
TABLE 206: Healgen Scientific: Company Profile
TABLE 207: Princeton BioMeditech Corporation: Company Profile
TABLE 208: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 209: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 210: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Future CLIA-Waived Test Menu Expansion
TABLE 211: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Pharmacy Test-to-Treat Outlook
TABLE 212: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Urgent Care and Physician Office Diagnostic Platform Outlook
TABLE 213: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Rural and Mobile Testing Outlook
TABLE 214: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 215: U.S. CLIA-Waived Point-of-Care Testing Devices Market: M&A and Strategic Partnership Outlook
TABLE 216: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 217: U.S. CLIA-Waived Point-of-Care Testing Devices Market: White-Space Opportunity Analysis
TABLE 218: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations for Device and Assay Manufacturers
TABLE 219: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations for Healthcare Providers and Testing Sites
TABLE 220: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 221: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 222: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 223: U.S. CLIA-Waived Point-of-Care Testing Devices Market: CLIA Waiver and U.S. Market Entry Strategy
TABLE 224: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Go-to-Market and Instrument Placement Strategy
TABLE 225: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 226: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Geographic Expansion and State Prioritization Strategy
TABLE 227: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Scope Limitation
TABLE 228: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 229: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Market Sizing Limitation
TABLE 230: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 231: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Regulatory and Reimbursement Data Limitation
TABLE 232: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 233: U.S. CLIA-Waived Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. CLIA-Waived Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Point-of-Care Device Procurement Decision Framework
FIGURE 12: U.S. CLIA-Waived Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. CLIA-Waived Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Test Category Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Test Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Blood Glucose and Diabetes Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Infectious Disease Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Cardiometabolic and Lipid Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Pregnancy and Fertility Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Coagulation and Hematology Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Drugs of Abuse and Toxicology Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Urinalysis, Renal and Other Waived Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Device & Platform Format Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Device & Platform Format Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Lateral Flow and Rapid Immunochromatographic Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Meter-and-Strip Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Cartridge-Based Analyzer Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Rapid Molecular Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Dipsticks, Digital Readers and Other Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Sample Type Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Sample Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Blood Sample Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Nasal and Oropharyngeal Swab Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Urine Sample Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Saliva and Oral Fluid Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Other Sample Types Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Physician Office Laboratories and Medical Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Urgent Care Centers, Retail Clinics and Pharmacies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Hospitals and Health-System Point-of-Care Locations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Community Health Centers and Public Health Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Long-Term Care, Nursing, Occupational and Other Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: CLIA Certificate of Waiver Testing-Site Economics Framework
FIGURE 46: Reimbursement and CPT Coding Landscape
FIGURE 47: Pharmacy Point-of-Care Testing Business Model Framework
FIGURE 48: Installed-Base and Recurring Consumables Economics
FIGURE 49: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 50: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: West Region U.S. CLIA-Waived Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 52: West Region Market Share Analysis by State, 2025
FIGURE 53: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: California CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Washington CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Arizona CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Colorado CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Oregon CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Utah CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Nevada CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: New Mexico CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Idaho CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Montana CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Wyoming CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Alaska CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Hawaii CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Northeast Region U.S. CLIA-Waived Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 68: Northeast Region Market Share Analysis by State, 2025
FIGURE 69: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: New York CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Massachusetts CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: New Jersey CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Pennsylvania CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Connecticut CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Maine CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Vermont CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New Hampshire CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Rhode Island CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: South Region U.S. CLIA-Waived Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 80: South Region Market Share Analysis by State, 2025
FIGURE 81: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Texas CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Florida CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Georgia CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: North Carolina CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Tennessee CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: South Carolina CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Alabama CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Mississippi CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Louisiana CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Arkansas CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Kentucky CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Oklahoma CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Virginia CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Maryland CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: West Virginia CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Delaware CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Midwest Region U.S. CLIA-Waived Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 99: Midwest Region Market Share Analysis by State, 2025
FIGURE 100: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Illinois CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Ohio CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Michigan CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Minnesota CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Indiana CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Wisconsin CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Missouri CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Iowa CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Kansas CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Nebraska CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: North Dakota CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: South Dakota CLIA-Waived Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 114: Company Positioning Matrix
FIGURE 115: Key Player Test Menu and Product Portfolio Benchmarking
FIGURE 116: Installed Base, Connectivity and Channel Benchmarking
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: CLIA-Waived Point-of-Care Testing Innovation Roadmap
FIGURE 119: Future Market Scenario Analysis, 2026–2035
FIGURE 120: Disruptive Technologies Impact Matrix
FIGURE 121: Future CLIA-Waived Test Menu Expansion Roadmap
FIGURE 122: Pharmacy Test-to-Treat Growth Roadmap
FIGURE 123: Rapid Molecular Diagnostics Opportunity Map
FIGURE 124: Rural and Mobile Point-of-Care Testing Opportunity Map
FIGURE 125: Investment Prioritization Matrix
FIGURE 126: White-Space Opportunity Matrix
FIGURE 127: Strategic Growth Roadmap for U.S. CLIA-Waived Point-of-Care Testing Companies
FIGURE 128: Go-to-Market and Instrument Placement Strategy Framework
FIGURE 129: Geographic Expansion and State Prioritization Framework
FIGURE 130: Product Positioning and Portfolio Expansion Framework
FIGURE 131: Report Scope and Disclaimer Framework